North China Pharmaceutical Co (NCPC) and its vitamin C production unit Hebei Welcome Pharmaceutical Co were ordered to pay $162.3 million in fines by a jury in Brooklyn, New York Thursday after being found guilty of price fixing, the Beijing Times reported Saturday.
Since late 2001, Chinese vitamin C manufacturers have acted in collusion to intentionally limit supply of vitamin C to the US market in order to manipulate prices, according to a lawsuit filed this month by two US companies, it said.
The case marks the first time a Chinese company has been found guilty in a trial over US antitrust claims, James Serota, one of the plaintiffs, told Bloomberg on Friday.
NCPC said the company would appeal the verdict, which it called unfair.
China's financial might takes shape
Top 10 Chinese cities with highest urbanization quality
Chinese investment in Africa: Digging deeper
Top 10 innovative cities in Asia-Pacific
Nation may limit gold to 2% of foreign reserves
Lu Zhaoxi named Alibaba's new CEO